| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Dihydroconiferyl alcohol targets cellular processes involved in proliferation, apoptosis, and cell cycle regulation in human colon cells. As a phenolic plant metabolite, it may exert its biological effects through antioxidant activity, free radical scavenging, and modulation of signaling pathways involved in cell growth and survival. The compound has been examined for anticancer effects, including inhibition of proliferation, induction of apoptosis, and cell cycle arrest. Its phenolic structure suggests it may interact with cellular redox systems and signaling pathways. Further studies are needed to identify specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Dihydroconiferyl alcohol has been examined for its effects on human colon cells. The compound exhibits anticancer effects including inhibition of proliferation, induction of apoptosis, and cell cycle arrest. As a phenolic compound, it may also have antioxidant activity and free radical scavenging properties. The compound is used as a research tool to study the biological activities of phenolic plant metabolites and their potential chemopreventive effects. Further in vitro studies are needed to fully characterize its mechanism of action.
|
| ln Vivo |
In vivo data for Dihydroconiferyl alcohol are limited. As a phenolic plant metabolite found in maple syrup, it may have potential health benefits related to its antioxidant and anticancer activities. Further in vivo studies are needed to evaluate the compound's efficacy, bioavailability, and safety. The compound is primarily used as a research tool for studying natural product pharmacology and cancer chemoprevention.
|
| Enzyme Assay |
In vitro cell-based assays for Dihydroconiferyl alcohol are conducted in human colon cell lines (e.g., HCT116, HT29, Caco-2). Cells are treated with Dihydroconiferyl alcohol at concentrations ranging from 1-100 µM for 24-72 hours. Cell proliferation is assessed by MTT or CCK-8 assays. Cell cycle analysis is performed by flow cytometry with propidium iodide staining. Apoptosis is evaluated by Annexin V/PI staining and caspase activation. Antioxidant activity is assessed by measuring reactive oxygen species (ROS) levels using fluorescent probes. Gene expression changes are analyzed by qPCR.
|
| Cell Assay |
Cell-based assays for Dihydroconiferyl alcohol are conducted in human colon cell lines. Cells are treated with Dihydroconiferyl alcohol at concentrations ranging from 1-100 µM for 24-72 hours. Cell viability is assessed by MTT or CCK-8 assays. Cell cycle distribution is analyzed by flow cytometry with propidium iodide staining. Apoptosis is evaluated by Annexin V-FITC/PI double staining and caspase-3/7 activity assays. Proliferation is assessed by BrdU incorporation or Ki67 staining. The compound's effects on signaling pathways (e.g., MAPK, PI3K/AKT) are analyzed by western blot.
|
| Animal Protocol |
In vivo animal experiments for Dihydroconiferyl alcohol would typically use mouse models of colorectal cancer or other cancer types. Animals would be administered Dihydroconiferyl alcohol via oral gavage or intraperitoneal injection. Tumor growth would be monitored. At study termination, tumors and tissues would be collected for histology and molecular analysis. Pharmacokinetic studies would be performed to determine exposure and bioavailability. The compound's chemopreventive and anticancer efficacy would be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Dihydroconiferyl alcohol are not extensively reported. As a phenolic compound with a molecular weight of 182.22 g/mol, it is expected to have moderate oral bioavailability. The compound appears as a white to almost white powder to crystal with a melting point of 59.0-65.0°C. Purity is typically ≥98%. Storage: typically at room temperature. The compound is found in maple syrup and has been examined for anticancer effects. Further PK studies would be required for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
Dihydroconiferyl alcohol is supplied for research use only and is not intended for human administration. Toxicity data are limited, but as a phenolic plant metabolite found in food sources (maple syrup), it is expected to have low toxicity. Standard laboratory safety precautions should be followed. No specific toxicological studies have been published. The compound should be handled with care and stored appropriately.
|
| References | |
| Additional Infomation |
Dihydroconiferyl is a phenolic compound with the structure 2-methoxyphenol substituted with a 3-hydroxypropyl group at the 4-position. It is a plant metabolite belonging to the primary alcohol and eugenol classes. It has been reported to be found in Pinus densiflora, Tsuga chinensis, and other organisms with available data. See also: Acai berry pulp (partial).
Dihydroconiferyl alcohol (CAS 2305-13-7) is a research compound supplied for laboratory use only. It is not an approved drug and has no clinical trial or marketing authorization status. The compound is a phenolic plant metabolite found in maple syrup. It has been examined for anticancer effects including inhibition of proliferation, induction of apoptosis, and cell cycle arrest in human colon cells. Purity is typically ≥98%. The compound appears as a white to almost white powder to crystal. |
| Molecular Formula |
C10H14O3
|
|---|---|
| Molecular Weight |
182.2164
|
| Exact Mass |
182.094
|
| CAS # |
2305-13-7
|
| PubChem CID |
16822
|
| Appearance |
White to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
339.8±27.0 °C at 760 mmHg
|
| Melting Point |
63-65°C
|
| Flash Point |
159.3±23.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
0.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MWOMNLDJNQWJMK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H14O3/c1-13-10-7-8(3-2-6-11)4-5-9(10)12/h4-5,7,11-12H,2-3,6H2,1H3
|
| Chemical Name |
4-(3-hydroxypropyl)-2-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~274.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4879 mL | 27.4394 mL | 54.8787 mL | |
| 5 mM | 1.0976 mL | 5.4879 mL | 10.9757 mL | |
| 10 mM | 0.5488 mL | 2.7439 mL | 5.4879 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
